To reveal whether PKG can be a target to restrain cell viability in melanoma, we tested cGMP analogues, which are known PKG activators and commercially available, as well as newly synthesized compounds (Figure 2A; Supplementary Table 1). This evidence concerns the gene PRKG1 and melanoma.